1. Figure 3 Proportion of patients for whom NEDA
was achieved at 2 years with disease-modifying therapies and AHSCT
Figure 3 | Proportion of patients for whom NEDA was achieved at 2 years with disease-modifying therapies and AHSCT. Red dots are the mean, bars represent 95% confidence intervals. The disease-modifying therapies have been approved or have been effective in phase III trials. Although studies included different patient populations, higher rates of no evidence of disease activity (NEDA) were achieved with autologous haematopoietic stem cell transplantation (AHSCT) than with any other disease-modifying therapy, including those that are considered to have high efficacy. The findings suggest that AHSCT has a more profound effect on disease activity than do current disease-modifying therapies.
Muraro, P. A. et al. (2017) Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
Nat. Rev. Neurol. doi: /nrneurol